<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Van De Donk, N.W.C.J.</style></author><author><style face="normal" font="default" size="100%">Lokhorst, H.M.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.</style></author><author><style face="normal" font="default" size="100%">Cavo, M.</style></author><author><style face="normal" font="default" size="100%">Morgan, G.</style></author><author><style face="normal" font="default" size="100%">Einsele, H.</style></author><author><style face="normal" font="default" size="100%">Kropff, M.</style></author><author><style face="normal" font="default" size="100%">Schey, S.</style></author><author><style face="normal" font="default" size="100%">Avet-Loiseau, H.</style></author><author><style face="normal" font="default" size="100%">Ludwig, H.</style></author><author><style face="normal" font="default" size="100%">Goldschmidt, H.</style></author><author><style face="normal" font="default" size="100%">Sonneveld, P.</style></author><author><style face="normal" font="default" size="100%">Johnsen, H.E.</style></author><author><style face="normal" font="default" size="100%">Bladé, J.</style></author><author><style face="normal" font="default" size="100%">San-Miguel, J.F.</style></author><author><style face="normal" font="default" size="100%">Palumbo, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Treatment of relapsed and refractory multiple myeloma in the era of novel agents</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Treatment Reviews</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">bortezomib</style></keyword><keyword><style  face="normal" font="default" size="100%">Guidelines</style></keyword><keyword><style  face="normal" font="default" size="100%">Lenalidomide</style></keyword><keyword><style  face="normal" font="default" size="100%">multiple myeloma</style></keyword><keyword><style  face="normal" font="default" size="100%">novel agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Refractory disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Relapse treatment</style></keyword><keyword><style  face="normal" font="default" size="100%">Thalidomide</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79953125606&amp;doi=10.1016%2fj.ctrv.2010.08.008&amp;partnerID=40&amp;md5=570ebf080c3ae8e2fb7d30fbfbfaeb1e</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">37</style></volume><pages><style face="normal" font="default" size="100%">266 - 283</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The introduction of the Immunomodulatory drugs (IMiDs) and proteasome inhibitors, used either as a single-agent or combined with classic anti-myeloma therapies, has improved the outcome for patients with relapsed myeloma. However, there is currently no generally accepted standard treatment for relapsed/refractory myeloma patients, partly because of the absence of trials comparing the efficacy of the novel agents in relapsed/refractory myeloma. Choice of a new treatment regimen depends on both patient and disease-specific characteristics. A lenalidomide-based regimen is the first choice in patients with neuropathy, while bortezomib has the highest efficacy in patients with renal insufficiency and is not associated with increased risk of thromboembolism. A second autologous stem cell transplantation (auto-SCT) can be applied in patients with a progression-free period of ≥18-24. months after the first auto-SCT. In high-risk relapse such as occurring early after auto-SCT consolidation with allogeneic SCT can be considered. In this review we provide an overview of the various salvage regimens and give recommendations for treatment of patients with relapsed/refractory myeloma in different clinical settings. © 2010 Elsevier Ltd.</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><notes><style face="normal" font="default" size="100%">Cited By :46Export Date: 21 February 2017</style></notes></record></records></xml>